When the patent of multinational giant expires, how about the domestic generic drug business?

Source: Merck, a global pharmaceutical giant, and Bristol Myers Squibb, a global drug giant, sold their patent drug of mAb in 2017 The patent of ibital (generic name, cetuximab) expired, which is being imitated by domestic pharmaceutical companies Foshan anpuze biomedical Co., Ltd has officially announced that its first project (cetuximab injection) has obtained the clinical approval document, and will soon carry out the first phase of clinical trial of cetuximab, and jointly released the new three board plan with Aijian securities According to the latest data from the State Food and drug administration, 7 enterprises have obtained the clinical approval of cetuximab Some analysts pointed out that in 2015, the sales volume of monoclonal antibody drugs (McAbs) in China was 7 billion yuan Although the compound growth rate in the past five years reached 34.4%, the current proportion of McAb drugs is only 9.7% With the expiration of patent drugs and the increase of domestic R & D efforts, it is expected to sprint to a market scale of more than 30 billion in the future Seven pharmaceutical companies want to seize the imitative business as the star drug in the field of anti-tumor Ibital was listed in the United States in 1997, and its global sales reached up to $1.996 billion in 2015 However, the drug was only commissioned in 2004 for sub packaging sales in China "Due to the high price of the imported drug, a course of treatment will cost 60000 to 80000 yuan, and the whole course will cost several hundred thousand yuan The high cost has suppressed the domestic demand At present, the drug is only covered by medical insurance in Tibet, and its sales in China are only 300 million yuan " Liang Huiqing, general manager of ampzer biomedicine, told Nandu At present, ampuzer has listed cetuximab drug research and development project as one of the strategic research and development projects, and it is expected to complete all clinical trials in the next four years As a matter of fact, there are not only anpuze companies that are trying to copy the patent of ebitur According to ge Liang, an expert in financing roadshow, in order to compete for the market cake of ebitur patent, 7 pharmaceutical companies have obtained clinical approval documents, including Qilu pharmaceutical, Foshan anpuze, Guilin Sanjin, Shanghai CITIC Guojian pharmaceutical, Shanghai Fuhong Hanlin biology, Harbin Pharmaceutical Group, Sichuan Kelun pharmaceutical For many domestic pharmaceutical companies, it is analyzed that the global biomedical industry is still in its infancy Although the domestic start-up is a little late, it is possible to catch up, which is a huge opportunity for domestic biomedical companies Because according to the rules, generic drugs usually cost a third as much as proprietary drugs Once the product is on the market, the selling price will be significantly lower than that of the same type of imported drugs Meanwhile, the company will enjoy the developed market of imported brand drugs, and will obtain a surprising sales revenue Take Kanghong pharmaceutical's monoclonal antibody heavy-duty bomb "conbercept ophthalmic injection" as an example After the successful development of the drug, the amazing performance in the past two years has attracted the attention of the industry According to the 2016 Kanghong pharmaceutical semi annual report, the first six months of this year's net sales of conbercept, which has only been listed for two years, have reached 220 million yuan, up 109% year on year This is in sharp contrast to the current situation that China's pharmaceutical industry is in a 10% downturn In addition, the listing of conbercept also forced the import of rapunzumab, the world's first brand in the field, to reduce the price by nearly 27% actively and substantially when the Chinese patent is far from due According to ge Liang, the global monoclonal antibody market shows explosive growth, from $3.2 billion in 2000 to $98 billion in 2015, with an annual compound growth rate of 25.76% It is estimated that the global monoclonal antibody sales will reach $220 billion by 2020 In addition, the market position of McAb in the global biological products industry has also increased from 2.5% in 1997 to 34.7% in 2015 At present, McAb has become the sub industry with the largest market share in the global biological products industry CIC consultants predict that by 2020, the market size of China's McAb industry will reach US $28 billion, and the annual compound growth rate from 2016 to 2020 will reach 30% Relevant information: ibital is a targeted drug for the treatment of colorectal cancer Ibital (cetuximab injection), which is sold in China, is registered in China by Merck, Germany, and is mainly used for the treatment of metastatic rectal cancer In the first-line treatment of metastatic colorectal cancer, the combination of ibital and FOLFOX has achieved the highest remission rate (81%) reported so far, and the clinical effect is significant Compared with traditional chemotherapy drugs, molecular targeted drugs such as ibital are just like precision guided biological missiles, which can attack tumor cells accurately and rarely damage normal cells In terms of mechanism, unlike traditional chemotherapy drugs, they have no serious side effects.